Orthocell US Expansion Drives Record Revenue and Growth Outlook
Orthocell Ltd (ASX:OCC) reported record revenue for FY2026, reaching A$13.2 million, a 44% increase year-over-year, driven by product sales in Australia and expanding international markets including the US, Thailand, Hong Kong, Singapore, and Canada. The June quarter revenue hit A$3.8 million, up 20% from the prior quarter. CEO Paul Anderson highlighted that the full financial benefit of the US rollout has not yet been realized, with an eight-person US team now in place and growing distributor interest. The company has A$44 million in cash to fund expansion and manufacturing, and is preparing for potential UK and EU approvals. Anderson expects a material revenue increase in coming quarters as surgeon and hospital adoption accelerates, describing the trajectory as a potential 'hockey-stick' growth scenario.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection